Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition
This study has been terminated.
(A total of three parts were planned for this study. The sponsor funded only Part 1, so that neither Part 2 nor Part 3 of this study has been conducted.)
University of Pennsylvania
Information provided by (Responsible Party):
Carsten Skarke, University of Pennsylvania
First received: October 24, 2008
Last updated: February 5, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been terminated.|
|Study Completion Date:||July 2013|
|Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther. 2012 Jun;91(6):986-93. doi: 10.1038/clpt.2012.3. Epub 2012 Jan 25.
Hirankarn S, Barrett JS, Alamuddin N, FitzGerald GA, Skarke C. GCG100649, a novel cyclooxygenase-2 inhibitor, exhibits a drug disposition profile in healthy volunteers compatible with high affinity to carbonic anhydrase-I/II: Preliminary dose-exposure relationsships to define clinical development strategies. 2013 Oct; 2 (4):379-386 Clin Pharm Drug Development.